Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

ClinicalTrials.gov ID: NCT04802837

Public ClinicalTrials.gov record NCT04802837. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double Blind, Active Controlled Study to Evaluate the Safety and Tolerability of Ridinilazole Compared With Vancomycin and to Assess the Pharmacokinetics of Ridinilazole in Adolescent Subjects (Aged 12 to <18 Years) With Clostridioides Difficile Infection

Study identification

NCT ID: NCT04802837
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Summit Therapeutics; Industry
Enrollment: 2 participants

Conditions and interventions

Conditions

Clostridioides Difficile Infection

Interventions

Ridinilazole Drug
Vancomycin Drug

Drug

Eligibility (public fields only)

Age range: 12 Years to 17 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 18, 2021
Primary completion: Sep 16, 2021
Completion: Sep 27, 2022
Last update posted: Aug 20, 2023

2021 – 2022

United States locations

U.S. sites: 18
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of California, Los Angeles (UCLA) David Geffen School of Medicine	Los Angeles	California	90095	—
Children's Hospital Orange County	Orange	California	92868	—
Continental Clinical Research	Miami	Florida	33144	—
Dynamic Medical Research LLC	Miami	Florida	33144	—
D&H National Research Centers	Miami	Florida	33155	—
HMD Research	Orlando	Florida	32819	—
Children's Center for Digestive Health	Atlanta	Georgia	30342	—
Snake River Research	Idaho Falls	Idaho	83404	—
Ann and Robert H Lurie Children's Hospital of Chicago	Chicago	Illinois	60611	—
University of Chicago - Comer Children's Hospital	Chicago	Illinois	60637	—
Indiana University Health - Riley Hospital for Children	Indianapolis	Indiana	46202	—
Boston Children's Hospital	Boston	Massachusetts	02115	—
Children's Hospital of Michigan	Detroit	Michigan	48201	—
Icahn School of Medicine at Mount Sinai	New York	New York	10029	—
DiGiovanna Institute for Medical Education and Research	New York	New York	11758	—
Stony Brook University Medical Center	Stony Brook	New York	11794	—
Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio	45229	—
University Hospitals Cleveland Medical Center - Rainbow Babies and Children's Hospital	Cleveland	Ohio	44106	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04802837, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 20, 2023 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04802837 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →